Clinical and experimental study of pulmonary fibrosis / Japan Scar Workshop


Papers of The 4th Japan Scar Workshop
10. Clinical and experimental study of pulmonary fibrosis Masahide Yasui Respiratory Medicine, Kanazawa Municipal Hospital
The events leading to scarring in the lungs in pulmonary fibrosis in some respects resemble the process of wound repair, as occurs in the skin injury. Therefore, I comment on the clinical and experimental study of pulmonary fibrosis. The clinical and pathological classification for idiopathic interstitial pneumonia was unified at the European Respiratory Society and American Thoracic Society in 2002. Idiopathic pulmonary fibrosis (IPF) is a fatal disorder with no effective therapy to date. However, treatment with pirfenidone improved pulmonary function of IPF. Pirfenidone attenuates Pirfenidone, which is an orally administered compound with anti-inflammatory, antioxidant, and antifibrotic properties. Experimental animal models have been used to study human pulmonary fibrosis. These models include the administration of intratracheal or intravenous bleomycin, intratracheal silica. Bleomycin-induced pulmonary fibrosis has been studied the most. Pulmonary fibrosis is evaluated by pathological scoring and hydroxyproline content of the lungs. The cellular composition and cytokine levels in bronchoalveolar lavage fluid are used for the evaluation of pulmonary inflammation . We examined the effects of angiotensin converting enzyme inhibitor (ACE-I),an angiotensin II type 1 receptor antagonist (AT1A) and an angiotensin II type 2 receptor antagonist (AT2A). ACE-I, AT1A and AT2A suppressed lung fibrosis and inflammation in BLM-induced pulmonary fibrosis in mice.
<< BACK	PAGE TOP